“…The dysregulation of complement has been implicated in a variety of adverse pregnancy outcomes including hypertensive diseases of pregnancy (Lynch et al, 2012; Lynch et al, 2008; Lynch, Wagner, Giclas, et al, 2016),antiphospholipid antibody syndrome associated fetal loss (Breen et al, 2012), recurrent fetal loss and PTB (Lynch et al, 2012; Lynch et al, 2011; Lynch, Wagner, Deterding, et al, 2016). In the hypertensive diseases of pregnancy, antiphospholipid syndrome, and PTB studies, complement dysregulation was determined by the discovery of elevated circulating plasma levels of complement activation fragments (e.g., C3a/Bb) in the presence of the select health complication.…”